CD24: A Novel Target for Cancer Immunotherapy

Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Sigle...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2022-07, Vol.12 (8), p.1235
Main Authors: Panagiotou, Emmanouil, Syrigos, Nikolaos K., Charpidou, Andriani, Kotteas, Elias, Vathiotis, Ioannis A.
Format: Article
Language:English
Subjects:
Antigens
Bacterial infections
Cancer immunotherapy
Cell adhesion
Cell growth
Cell therapy
Chemotherapy
Chimeric antigen receptors
Clinical trials
Colorectal cancer
Cytotoxicity
Immunotherapy
Kinases
Ligands
Lymphocytes
Lymphocytes T
Macrophages
Medical prognosis
Metastasis
Monoclonal antibodies
Natural killer cells
Nervous system
Ovarian cancer
Phagocytosis
Precision medicine
Proteins
Regulation
Review
Sepsis
Signal transduction
Stem cells
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Siglec-10 interaction has been implicated in tumor immune evasion, inhibiting macrophage-mediated phagocytosis as well as natural killer (NK) cell cytotoxicity. CD24 blockade has shown promising results in preclinical studies. Although there are limited data on efficacy, monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in two clinical trials. Other treatment modalities evaluated in the preclinical setting include antibody–drug conjugates and chimeric antigen receptor (CAR) T cell therapy. In this review, we summarize current evidence and future perspectives on CD24 as a potential target for cancer immunotherapy.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12081235